Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Diagnostic and Prognostic Role of HBME-1, Galectin-3, and &bgr;-Catenin in Poorly Differentiated and Anaplastic Thyroid Carcinomas

Diagnostic and Prognostic Role of HBME-1, Galectin-3, and &bgr;-Catenin in Poorly Differentiated... RESEARCH ARTICLE Diagnostic and Prognostic Role of HBME-1, Galectin-3, and b-Catenin in Poorly Differentiated and Anaplastic Thyroid Carcinomas Esther D. Rossi, MD, PhD,* Patrizia Straccia, BD,* Marianna Palumbo, MD,* Egidio Stigliano, BD,* Luca Revelli, MD,w Celestino P. Lombardi, MD,w Giuseppe Santeusanio, MD,z Alfredo Pontecorvi, MD, PhD,y and Guido Fadda, MD, MIAC* Key Words: poorly differentiated thyroid carcinoma, anaplastic Aim: Thyroid cancer represents the first endocrine malignant thyroid carcinoma, immunohistochemistry, prognosis neoplasm, accounting for 1% of human malignancy. The ma- (Appl Immunohistochem Mol Morphol 2013;21:237–241) jority of which are well-differentiated cancer representing up to 90% of thyroid cancer and pursuing a favorable clinical course. The groups of poorly differentiated thyroid cancer (PDC) and hyroid cancer represents the most frequent malignant anaplastic thyroid cancer (ATC) have a poor outcome and need Tendocrine neoplasm accounting for 1% of all human a strict clinical surveillance. carcinomas with an incidence of up to 60 cases per million Materials and Methods: Thirty-four cases including 23 PDC/ people a year, which ranks this tumor among the 5 most insular cancer and 9 ATC were examined for the expression of important malignant neoplasms in patients between 15 an immunohistochemical panel made up by HBME-1, galectin- and 45 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Diagnostic and Prognostic Role of HBME-1, Galectin-3, and &bgr;-Catenin in Poorly Differentiated and Anaplastic Thyroid Carcinomas

Loading next page...
 
/lp/wolters-kluwer-health/diagnostic-and-prognostic-role-of-hbme-1-galectin-3-and-bgr-catenin-in-7EKelxf9J8

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2012 by Lippincott Williams & Wilkins
ISSN
1541-2016
DOI
10.1097/PAI.0b013e3182688d0f
pmid
23235344
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE Diagnostic and Prognostic Role of HBME-1, Galectin-3, and b-Catenin in Poorly Differentiated and Anaplastic Thyroid Carcinomas Esther D. Rossi, MD, PhD,* Patrizia Straccia, BD,* Marianna Palumbo, MD,* Egidio Stigliano, BD,* Luca Revelli, MD,w Celestino P. Lombardi, MD,w Giuseppe Santeusanio, MD,z Alfredo Pontecorvi, MD, PhD,y and Guido Fadda, MD, MIAC* Key Words: poorly differentiated thyroid carcinoma, anaplastic Aim: Thyroid cancer represents the first endocrine malignant thyroid carcinoma, immunohistochemistry, prognosis neoplasm, accounting for 1% of human malignancy. The ma- (Appl Immunohistochem Mol Morphol 2013;21:237–241) jority of which are well-differentiated cancer representing up to 90% of thyroid cancer and pursuing a favorable clinical course. The groups of poorly differentiated thyroid cancer (PDC) and hyroid cancer represents the most frequent malignant anaplastic thyroid cancer (ATC) have a poor outcome and need Tendocrine neoplasm accounting for 1% of all human a strict clinical surveillance. carcinomas with an incidence of up to 60 cases per million Materials and Methods: Thirty-four cases including 23 PDC/ people a year, which ranks this tumor among the 5 most insular cancer and 9 ATC were examined for the expression of important malignant neoplasms in patients between 15 an immunohistochemical panel made up by HBME-1, galectin- and 45

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: May 1, 2013

There are no references for this article.